Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A pill bottle on a desk with patent documents in a natural light setting.

May 28, 2026

Redwood AI and Resilience Biosciences Forge a Patent-Savvy Path to Non-Opioid Therapies

Redwood AI and Resilience Biosciences are pioneering a novel approach in drug discovery by integrating patent analysis into the early stages of developing non-opioid therapies.This collaboration focuses on addressing the urgent need for non-addictive treatments for opioid withdrawal and associated neurocognitive symptoms. By utilizing Redwood's Reactosphere platform, Resilience Biosciences aims to streamline the drug development process, ensuring that potential candidates are not only biological
A laboratory vial filled with a colorful liquid in a dimly lit lab setting.

May 27, 2026

Verge, following trial failure, rebrands its AI drug discovery ambitions

Verge Genomics is undergoing a significant transformation, rebranding itself as Verge Labs to focus on providing data-driven insights for drug developers. This shift comes after a disappointing trial outcome for its AI-driven ALS treatment, VRG50635, which failed to demonstrate efficacy in patients.The rebranding follows a drastic reduction in workforce, with about 90% of employees laid off. CEO Alice Zhang emphasized that setbacks are common in drug development, whether through AI or traditiona
A petri dish with a drug compound in a lab setting

May 27, 2026

Isomorphic Labs has turned AI drug discovery into a 2.1B capital story

Isomorphic Labs has successfully raised $2.1 billion in a Series B funding round, reflecting strong investor confidence in its AI-driven drug discovery platform.The Alphabet-supported company, helmed by Demis Hassabis, announced that the funding will enhance its AI drug design engine, IsoDDE, and expand its global reach while advancing its pipeline towards clinical trials. This significant financial backing, led by Thrive Capital along with other notable investors, underscores a growing belief t
A minimalist illustration of a pill and a molecule on a solid background.

May 27, 2026

Ex-Palantir team bags $12M seed to build the AI operating system pharma has been missing

Perceptic, a London-based startup, has raised $12 million in seed funding to develop an integrated AI platform aimed at revolutionizing the drug development process, which is currently hindered by fragmented systems. This initiative seeks to streamline the journey of a drug from initial discovery through clinical trials, addressing inefficiencies that plague many pharmaceutical companies.The founders of Perceptic, who previously played pivotal roles in developing Palantir’s AI products for life
Minimalist illustration of an RNA strand and data points

May 26, 2026

Lexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug Discovery

A recent episode of the Beyond Biotech podcast features insights from Dr. Stéphane Barges, CEO of Lexogen, discussing the pivotal role of RNA sequencing in AI-driven drug discovery.In the podcast, Dr. Barges emphasizes that high-quality data tailored for AI applications is crucial for enhancing target identification and decreasing drug development failures. He advocates for datasets that are meticulously designed to address specific scientific questions, underscoring the importance of precision
A test tube with a colorful chemical solution on a lab bench

May 26, 2026

Exclusive: Ex-Palantir AI execs raise $12 million seed round for Perceptic, a startup automating drug discovery

Perceptic, a startup founded by former Palantir executives, has emerged from stealth mode with a $12 million seed funding round aimed at revolutionizing drug discovery through an end-to-end AI platform. The company, which has already garnered interest from major pharmaceutical firms, is designed to streamline the drug development process from discovery to clinical trial design.The funding round was led by Accel, with participation from Air Street Capital and Elder Gull. Although the company has
A minimalist representation of a bispecific antibody in flat design.

May 26, 2026

Biomunex Pharmaceuticals Embraces AI with Two New Strategic Collaborations

Biomunex Pharmaceuticals is enhancing its research capabilities through two new partnerships with AI-focused firms, Gordion Bioscience and Tangramed Biotech.The collaborations aim to integrate artificial intelligence into Biomunex's scientific workflows, particularly in the realm of immunotherapy development. By leveraging AI technologies, the company seeks to expedite the discovery and refinement of innovative treatments for cancer, focusing on bispecific and multi-specific antibodies.These str
A minimalist representation of a drug compound in a dark palette.

May 26, 2026

AI drug discovery deal targets faster biotech hit validation

A new partnership between Concept Life Sciences and OpenBench aims to revolutionize the early stages of drug discovery for biotech firms by leveraging artificial intelligence to streamline hit validation processes.The collaboration combines OpenBench’s AI-driven structure-based platform with Concept Life Sciences’ expertise in medicinal chemistry and validation services. This integrated approach is designed to expedite the transition from target identification to validated hit series in just six
A drug compound in a glass vial on a lab bench with shelves of reagents in the background.

May 25, 2026

Machine learning brings speed to pharma’s slowest pipeline

Machine learning is revolutionizing the drug discovery process by enhancing efficiency in target identification and compound selection, yet it faces challenges in validation and integration with existing workflows.Recent research published in *Pharmaceuticals* emphasizes the transformative role of machine learning (ML) in drug discovery, particularly in the early stages where researchers select targets and evaluate molecular candidates. The study advocates for ML as a complementary tool to exper
A vial of medication on a lab bench

May 25, 2026

Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer?

Nvidia's recent investment in Generate Biomedicines highlights a significant shift in the biotech landscape, particularly in AI-driven drug development. The $10.40 million funding aims to bolster Generate's clinical pipeline, which includes advanced therapies for severe asthma and oncology, currently under FDA Fast Track status.This investment not only validates Generate Biomedicines' approach but also emphasizes the growing traction of AI in real-world drug discovery. However, the company faces
A small-molecule drug compound on a lab bench in a biopharmaceutical lab

May 24, 2026

Redwood AI’s Data Boom and Defense Push Contrast With Silent Pharma Pact

Redwood AI is making strides in both the defense and pharmaceutical sectors, yet its stock remains volatile due to a lack of financial clarity.The Canadian AI company has recently announced a partnership with Resilience Biosciences, a biopharmaceutical firm focused on developing non-opioid therapies. This collaboration will utilize Redwood’s advanced software for designing small-molecule drug candidates. However, the absence of financial specifics in the announcement has left investors uncertain
A vial of enzyme sample on a lab bench with shelves of reagents in the background.

May 21, 2026

Imperagen’s £5M Bid Powers AI Enzyme Design Leap

Imperagen has secured £5 million in funding to enhance its AI-driven enzyme design platform, aiming to revolutionize the biocatalyst development landscape.The latest funding round brings Imperagen's total to £8.5 million since its inception in 2021, allowing the company to expand its research and development efforts in AI enzyme design. This financial boost will support hiring in key areas such as computational chemistry and automation, with plans to double its workforce within the next year. Th